8OY1
Structure of the human Guanine Nucleotide-Binding Protein G(K) Subunit Alpha
8OY1 の概要
| エントリーDOI | 10.2210/pdb8oy1/pdb |
| 分子名称 | Guanine nucleotide-binding protein G(i) subunit alpha-3, GUANOSINE-5'-DIPHOSPHATE (2 entities in total) |
| 機能のキーワード | modulator, gpcr, signaling protein |
| 由来する生物種 | Homo sapiens (human) |
| タンパク質・核酸の鎖数 | 1 |
| 化学式量合計 | 37336.13 |
| 構造登録者 | Medrano, F.J.,Blanco, F.J.,Ferreras-Gutierrez, M.O. (登録日: 2023-05-03, 公開日: 2024-05-15, 最終更新日: 2025-01-15) |
| 主引用文献 | Ferreras-Gutierrez, M.,Minguez-Toral, M.,Ibanez de Opakua, A.,Martin-Santamaria, S.,Garcia-Marcos, M.,Medrano, F.J.,Blanco, F.J. Integrated NMR-crystallography-computational approach for molecular recognition studies of human G alpha i3 protein by a small molecule inhibitor. Int.J.Biol.Macromol., 290:138977-138977, 2024 Cited by PubMed Abstract: The small molecule IGGi-11 targets Gαi subunits of heterotrimeric guanine nucleotide-binding proteins. Gα subunits are activated by G-protein-coupled receptors in response to extracellular stimuli by accelerating the exchange of GDP for GTP, but they are also activated by intracellular proteins like GIV, of which elevated levels correlate with increased cell migration and cancer metastasis. IGGi-11 disrupts the interaction of Gαi proteins with GIV and inhibits pro-invasive traits of metastatic breast cancer cells without interfering with GPCR signaling. IGGi-11 is a competitive inhibitor but binds Gαi3 with a 10-fold lower affinity than GIV. To guide the design of higher affinity inhibitors, we aimed at obtaining high-resolution structural data on the complex. To facilitate its crystallization, we have removed the most flexible residues at the chain ends of Gαi3, identified by NMR. While Gαi3 crystals grown with excess IGGi-11 did not show the bound compound, computational docking and molecular dynamics simulations identified the interactions driving the molecular recognition. This approach revealed heterogeneous binding due to the symmetry of IGGi-11 chemical structure and to the elongated shape and flexibility of the binding site. Our results suggest that chemical modifications breaking IGGi-11 symmetry might yield inhibitors with higher affinity and potential as antimetastatic drugs. PubMed: 39706421DOI: 10.1016/j.ijbiomac.2024.138977 主引用文献が同じPDBエントリー |
| 実験手法 | X-RAY DIFFRACTION (3.34 Å) |
構造検証レポート
検証レポート(詳細版)
をダウンロード






